New onset refractory status epilepticus (NORSE)
- PMID: 30482654
- DOI: 10.1016/j.seizure.2018.09.018
New onset refractory status epilepticus (NORSE)
Abstract
Purpose: To summarize the clinical features, suggested work-up, treatment and prognosis of new-onset refractory status epilepticus (NORSE), a condition recently defined as the occurrence of refractory status epilepticus (RSE) in a patient without active epilepsy, and without a clear acute or active structural, toxic or metabolic cause; and of the related syndrome of febrile infection-related epilepsy syndrome (FIRES), also recently defined as a subgroup of NORSE preceded by a febrile illness between 2 weeks and 24 h prior to the onset of RSE.
Method: Narrative review of the medical literature about NORSE and FIRES.
Results: NORSE and FIRES mainly affect school-age children and young adults. A prodromal phase with flu-like symptoms precedes the SE onset in two third of NORSE cases, and by definition in all FIRES. Status epilepticus usually starts with repeated focal seizures with secondary bilateralization. Most cases evolve to super RSE (SRSE) and have unfavorable outcome, with short-term mortality of 12-27%, long-term disability and epilepsy. No specific imaging or laboratory abnormalities have been identified so far that allows an early diagnosis and half of adult cases remain of unknown etiology. A standardized diagnostic algorithm is provided and. Autoimmune encephalitis is the most frequent identified cause. In the absence of specific diagnosis, immunotherapy could be tried in addition to antiepileptic treatment.
Conclusions: This review presents the rare but devastating syndrome of NORSE, including the subcategory of FIRES. Early recognition with complete work-up is primordial to identify the underlying cause and promptly start appropriate treatment.
Keywords: Epilepsy; Epileptic encephalopathy; FIRES; NORSE; Refractory status epilepticus.
Copyright © 2018. Published by Elsevier Ltd.
Similar articles
-
Febrile Infection-Related Epilepsy Syndrome (FIRES): An Overview of Treatment and Recent Patents.Recent Pat Inflamm Allergy Drug Discov. 2018;12(2):128-135. doi: 10.2174/1872213X12666180508122450. Recent Pat Inflamm Allergy Drug Discov. 2018. PMID: 29745347 Review.
-
Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort).Epilepsia. 2021 Jul;62(7):1629-1642. doi: 10.1111/epi.16950. Epub 2021 Jun 6. Epilepsia. 2021. PMID: 34091885 Free PMC article.
-
Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions.Epilepsia. 2018 Apr;59(4):739-744. doi: 10.1111/epi.14016. Epub 2018 Feb 5. Epilepsia. 2018. PMID: 29399791 Review.
-
New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives.Epilepsia. 2018 Apr;59(4):745-752. doi: 10.1111/epi.14022. Epub 2018 Feb 24. Epilepsia. 2018. PMID: 29476535 Review.
-
New onset refractory status epilepticus: State of the art.Rev Neurol (Paris). 2022 Jan-Feb;178(1-2):74-83. doi: 10.1016/j.neurol.2021.12.005. Epub 2022 Jan 12. Rev Neurol (Paris). 2022. PMID: 35031143 Review.
Cited by
-
The Increased Interleukin-6 Levels Can Be an Early Diagnostic Marker for New-Onset Refractory Status Epilepticus.J Epilepsy Res. 2022 Dec 30;12(2):78-81. doi: 10.14581/jer.22015. eCollection 2022 Dec. J Epilepsy Res. 2022. PMID: 36685741 Free PMC article.
-
Ketogenic diet (KD) therapy in the acute phase of febrile infection-related epilepsy syndrome (FIRES): a case report.Transl Pediatr. 2021 Sep;10(9):2392-2397. doi: 10.21037/tp-21-121. Transl Pediatr. 2021. PMID: 34733679 Free PMC article.
-
Editorial: Advances in diagnosing and treating new-onset refractory status epilepticus (NORSE).Front Neurol. 2023 Aug 30;14:1270702. doi: 10.3389/fneur.2023.1270702. eCollection 2023. Front Neurol. 2023. PMID: 37712084 Free PMC article. No abstract available.
-
NORSE, FIRES, and a Polygenic Trickle of Autoimmunity.Ann Neurol. 2025 Feb;97(2):386-387. doi: 10.1002/ana.27148. Epub 2024 Dec 7. Ann Neurol. 2025. PMID: 39644168 Free PMC article. No abstract available.
-
Early initiation of intravenous cyclophosphamide and one-year outcome in super-refractory cryptogenic-new onset refractory status epilepticus.Epilepsia Open. 2025 Feb;10(1):307-313. doi: 10.1002/epi4.13055. Epub 2024 Dec 19. Epilepsia Open. 2025. PMID: 39701580 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources